Fixed-dose combination (antiretroviral)

From Wikipedia, the free encyclopedia

Fixed-dose combinations of antiretrovirals are multiple antiretroviral drugs combined into a single pill, which helps reduce pill burden. They may combine different classes of antiretrovirals or contain only a single class. Licensed fixed-dose combinations are shown in the table below.

Brand Name	Drug Names (INN)	Date of FDA Approval	Company
Combivir	zidovudine + lamivudine	September 26, 1997	GlaxoSmithKline
Trizivir	abacavir + zidovudine + lamivudine	November 15, 2000	GlaxoSmithKline
Kaletra	lopinavir + ritonavir	September 15, 2000^[1]	Abbott Laboratories
Epzicom (in USA) Kivexa (in Europe)	abacavir + lamivudine	August 2, 2004	GlaxoSmithKline
Truvada	emtricitabine + tenofovir	August 8, 2006^[2]	Gilead Sciences
Atripla	efavirenz + emtricitabine + tenofovir	July 12, 2006^[3]	Gilead Sciences Bristol-Myers Squibb
Complera	rilpivirine + emtricitabine + tenofovir	August 10, 2011^[4]	Gilead Sciences Johnson & Johnson
Stribild	elvitegravir + cobicistat + emtricitabine + tenofovir	August 27, 2012	Gilead Sciences

References

↑ "FDA approval of new formulation of Kaletra". FDA. October 28, 2005. "The original formulation was approved on September 15, 2000"
↑ "Traditional approval of Viread and Truvada". FDA. March 8, 2006. "VIREAD and TRUVADA had received accelerated approval on Oct. 26, 2001 and August 2, 2004, respectively"
↑ "FDA approval of Atripla, 3-drug fixed dose combination antiretroviral". FDA. July 12, 2006.
↑ "Approval of Complera: emtricitabine/rilpivirine/tenofovir DF fixed dose combination". FDA. August 10, 2011.

Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)

Entry/fusion inhibitors
(Discovery & development)

gp41 (Enfuvirtide)
CCR5 (Maraviroc
Vicriviroc^†, Cenicriviroc^†, PRO 140^†)
CD4 (Ibalizumab^†)

Reverse-transcriptase
inhibitors (RTIs)

Nucleoside & nucleotide (NRTI)	Nucleoside analogues/NARTIs: Abacavir (ABC)°^# Emtricitabine (FTC)°^# Lamivudine (3TC)°^# Didanosine (ddI)^# Zidovudine (AZT)^# Apricitabine^† Stampidine^† Elvucitabine^† Racivir^† Amdoxovir^† Stavudine (d4T)^# Zalcitabine (ddC)^◊ Festinavir^† Nucleotide analogues/NtRTIs: Tenofovir disoproxil fumarate (TDF)°^# Tenofovir alafenamide fumarate (TAF)^†

Non-nucleoside (NNRTI) (Discovery & development)	(1st generation) Efavirenz (EFV)°^# Nevirapine (NVP)^# Loviride^◊ Delavirdine (DLV)^◊ (2nd generation) diarylpyrimidines (Etravirine Rilpivirine) Lersivirine^†

Integrase inhibitors

Maturation inhibitors

Bevirimat^†

Protease Inhibitors (PI)
(Discovery and development)

1st generation	Fosamprenavir° Lopinavir°^# Nelfinavir^# Ritonavir^# Saquinavir^# Amprenavir^◊ Indinavir^◊^#

2nd generation	Atazanavir° Darunavir° Tipranavir

Combined formulations

Experimental agents

Uncoating inhibitors	TRIM5alpha (gene)

Transcription inhibitors	Tat antagonists

Translation inhibitors	Trichosanthin

Other	Abzyme Calanolide A Ceragenin Cyanovirin-N Diarylpyrimidines Epigallocatechin gallate (EGCG) Foscarnet Griffithsin Hydroxycarbamide Miltefosine Portmanteau inhibitors Seliciclib^† Synergistic enhancers Tre recombinase Zinc finger protein transcription factor KP-1461^† Cobicistat^†

Failed agents	Dexelvucitabine Capravirine Emivirine Lodenosine Atevirdine Brecanavir Aplaviroc

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

°DHHS preferred first-line agent. ^◊Formerly or rarely used agent.

M: VIR

virs(prot)/clss

cutn/syst (hppv/hiva, infl/zost/zoon)/epon

drug (dnaa, rnaa, rtva, vacc)

This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.

Fixed-dose combination (antiretroviral)

See also

References